reports
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; November 21, 2024 – (Nasdaq: GMAB) announced today that the Board decided to grant 10,273 restricted stock units and 10,853 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 1,447.50...
- Rune Majlund Dahl
Genmab (Buy, TP: DKK2500.00) - Still awaiting CD-38 decision
Q3 revenue missed our expectations, but operating profit exceeded due to lower operating costs. 2024 guidance for revenue was raised to DKK21.1bn–21.7bn; for opex was narrowed downwards to DKK14.1bn–14.4bn (due to portfolio prioritisation); and for operating profit, narrowed to the high end of DKK6.2bn–7.1bn. Investor focus was on JNJ’s upcoming opt-in decision (data submission expected end-2024). We reiterate our BUY and DKK2,500 target price.
Genmab Announces Financial Results for the First Nine Months of 2024
Genmab Announces Financial Results for the First Nine Months of 2024 November 6, 2024 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2024 Highlights European Commission (EC) granted conditional marketing authorization for TEPKINLY® (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapyGenmab announced that it will assume sole responsibility for the continued development and potential commercialization of acasunlimabGenmab revenue increased 29% com...
Genmab to Present at Jefferies London Healthcare Conference
Genmab to Present at Jefferies London Healthcare Conference Media ReleaseCOPENHAGEN, Denmark; November 5, 2024 (Nasdaq: GMAB) announced today that its Chief Executive Officer, Jan van de Winkel, Ph.D. and Chief Financial Officer, Anthony Pagano will take part in a fireside chat at the Jefferies London Healthcare Conference on November 19, 2024 at 4:30 PM CET / 10:30 AM EST. A webcast of the event will be available on Genmab’s website at . About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving...
Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-b...
Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting Media ReleaseCOPENHAGEN, Denmark; November 5, 2024 More than 20 abstracts, including four oral presentations, with new clinical data across lines of therapy and subgroups of non-Hodgkin’s lymphoma (NHL) patientsNew and updated data from EPCORE® clinical trial program reinforce the potential of epcoritamab as a monotherapy and in combination to treat multiple B-cell malignancies across lines of therapy (Nasdaq: GMAB) announced today more...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarte...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024 Company Announcement Net sales of DARZALEX® in the third quarter of 2024 totaled USD 3,016 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; October 15, 2024 – (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson were USD 3,016 millio...
- Rune Majlund Dahl
Genmab (Buy, TP: DKK2500.00) - 2024 guidance likely to narrow
We forecast Q3 sales c1.5% above consensus, an operating profit margin of 31.8% (consensus 31.5%), and net profit c6.1% below consensus, hurt by a net financial loss. We expect Genmab to narrow its 2024 guidance for revenue of DKK20.7bn–21.7bn and operating profit of DKK5.1bn–6.4bn. We expect investor focus to be on HexaBody-CD38, and we view J&J’s opt-in decision as a clearing event. We reiterate our BUY but have lowered our target price to DKK2,500 (2,600).
Major Shareholder Announcement
Major Shareholder Announcement Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; October 4, 2024 – (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Baillie Gifford & Co has informed us that, as of October 3, 2024, Baillie Gifford & Co held the voting rights to 3,301,530 shares in Genmab A/S, which amounts to 4.99% of the share capital and voting rights in Genmab A/S. About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improvi...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; September 26, 2024 – (Nasdaq: GMAB) announced today that the Board decided to grant 23,954 restricted stock units and 13,915 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 1,597.5...
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tum...
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial Media ReleaseCOPENHAGEN, Denmark; September 15, 2024 Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion cohortResponses with Rina-S were observed across FRα expression levels Phase 3 trial will further evaluate the safety and efficacy of Rina-S at 120 mg/m2 in patients with advanced ovarian cancer (Nasd...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; September 10, 2024 – (Nasdaq: GMAB) will increase its share capital by 11,729 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 4,623 shares at DKK 1,025.00,3,656 shares at DKK 1,032.00,561 shares at DKK 1,050.00,1,645 shares at DKK 1,334.50,1,015 shares at DKK 1,432.00, a...
Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conf...
Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference Media ReleaseCOPENHAGEN, Denmark; August 26, 2024 (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan van de Winkel, Ph.D. and Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference at 1:05 PM EDT / 7:05 PM CEST on September 4, 2024. A webcast of the event, which will include brief opening remarks followed by a question-and-answer session, will be available on Genmab’s website at . About Genmab Genmab is an inter...
TEPKINLY® (epcoritamab) Receives Second European Commission Approval f...
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma Company Announcement TEPKINLY is the first and only subcutaneous bispecific antibody approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy COPENHAGEN, Denmark; August 19, 2024 – (Nasdaq: GMAB) today announced that the European Commission (EC) has granted conditional marketing authorization for TE...
Genmab Announces Changes to its Executive Committee
Genmab Announces Changes to its Executive Committee Media Release COPENHAGEN, Denmark; August 16, 2024 Rayne Waller joins as Executive Vice President and Chief Technology OfficerBrad Bailey appointed as Executive Vice President and Chief Commercial OfficerAnthony Mancini, Executive Vice President and Chief Operating Officer, will leave Genmab to pursue other opportunities (Nasdaq: GMAB) today announced changes to its Executive Committee to support Genmab’s growth and evolution into a fully integrated biotech innovation powerhouse. Genmab’s Executive Committee will include Ra...
Transactions with shares and linked securities in Genmab A/S made by m...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement COPENHAGEN, Denmark; August 13, 2024 – (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behal...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; August 13, 2024 – (Nasdaq: GMAB) will increase its share capital by 28,193 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 107 shares at DKK 962.00,27,188 shares at DKK 1,032.00,279 shares at DKK 1,050.00,125 shares at DKK 1,334.50,484 shares at DKK 1,432.00, and10...
- Rune Majlund Dahl
Genmab (Buy, TP: DKK2600.00) - Solid underlying Q2 performance
Q2 revenue and operating profit beat our estimates and consensus, driven by higher-than-expected product-related royalties and solid net product sales. The 2024 guidance was raised to revenue of DKK20.5bn–21.7bn, opex of DKK14.1bn–14.7bn (mostly reclassification and M&A-related), and operating profit of DKK4.9bn–6.7bn. The investor focus was on BioNTech’s decision to opt out of the acasunlimab programme. We reiterate our BUY and DKK2,600 target price.
Genmab Announces Financial Results for the First Half of 2024
Genmab Announces Financial Results for the First Half of 2024 August 8, 2024 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2024 Highlights Completed acquisition of ProfoundBio Inc (ProfoundBio), granting Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel antibody-drug conjugate technology platforms The U.S. Food and Drug Administration (U.S. FDA) approved EPKINLY® (epcoritamab-bysp) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after...
Genmab Updates 2024 Financial Guidance
Genmab Updates 2024 Financial Guidance Company Announcement Genmab updates its 2024 financial guidanceIncrease in revenue driven by higher royalties and reimbursement revenueIncrease in operating profit excluding acquisition and integration charges, driven by higher revenue and focused investments COPENHAGEN, Denmark; August 8, 2024 – (Nasdaq: GMAB) announced today that it is updating its 2024 financial guidance last published on May 2, 2024, following the acquisition of ProfoundBio, Inc. (ProfoundBio). The revised guidance reflects an updated revenue outlook, incremental R&D investment...
Genmab Takes Full Control of Acasunlimab Development Program
Genmab Takes Full Control of Acasunlimab Development Program Company Announcement Genmab to assume sole responsibility for the continued development and potential commercialization of acasunlimab BioNTech has opted not to participate in the further development of the acasunlimab program under the parties’ existing collaboration agreementThe overall collaboration between the companies to continue unchanged COPENHAGEN, Denmark; August 5, 2024 – (Nasdaq: GMAB) announced today that it will assume sole responsibility for the continued development and potential commercialization of acasunlimab...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.